Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...103104105106107108109110111112113...123124»
  • ||||||||||  Halaven (eribulin mesylate) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial primary completion date, Metastases:  Eribulin and Lenvatinib in Advanced Solid Tumors (clinicaltrials.gov) -  Mar 24, 2020   
    P2,  N=32, Active, not recruiting, 
    Initiation date: Feb 2020 --> May 2020 Trial primary completion date: Dec 2019 --> Dec 2020
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Retrospective data, Journal:  Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinoma. (Pubmed Central) -  Mar 22, 2020   
    Patients with thyroid dysfunction had better prognosis. Based on these results, in patients administered with lenvatinib, there is need for careful assessment for the possibility of thyroid dysfunction from the onset of treatment.
  • ||||||||||  Journal:  Comparison of autophagy inducibility in various tyrosine kinase inhibitors and their enhanced cytotoxicity via inhibition of autophagy in cancer cells in combined treatment with azithromycin. (Pubmed Central) -  Mar 21, 2020   
    We previously reported that gefitinib (GEF) and imatinib (IMA) induce autophagy in epidermal growth factor receptor (EGFR) knock-out A549 and non-BCR-ABL-expressing leukemia cell lines, respectively...We established stable clones expressing the GFP-LC3-mCherry-LC3ΔG plasmid in A549, PC-9, and CAL 27 cell lines and assessed autophagy inducibility by monitoring the fluorescent ratios of GFP-LC3 to mCherry-LC3ΔG using an IncuCyte live cell imaging system during exposure to TKIs viz; GEF, osimertinib (OSI), lapatinib (LAP), lenvatinib (LEN), sorafenib (SOR), IMA, dasatinib (DAS), and tivantinib (TIV)...However, once induced, they appeared to have cytoprotective functions. Thus, blocking TKI-induced autophagy with AZM may improve the therapeutic effect of TKIs in cancer cells.
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Biomarker, Journal, IO Biomarker:  Systemic treatment of advanced hepatocellular cancer: new hope on the horizon. (Pubmed Central) -  Mar 20, 2020   
    Further development of novel combinations of these new agents and predictive/prognostic biomarkers are being explored. Efforts should also be made to tailor treatment to individual patients based on aetiology, clinical and molecular factors.
  • ||||||||||  Afinitor (everolimus) / Novartis, Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Retrospective data, Review, Journal:  Targeted therapies for previously treated advanced or metastatic renal cell carcinoma: systematic review and network meta-analysis. (Pubmed Central) -  Mar 18, 2020   
    The trial is in progress. Lenvatinib with everolimus, cabozantinib and nivolumab are effective in prolonging the survival for people with amRCC subsequent to VEGF-targeted treatment, but there is considerable uncertainty about how they compare to each other and how much better they are than axitinib and sorafenib.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Clinical, Journal:  Effectiveness and toxicity of lenvatinib in refractory thyroid cancer: Dutch real-life data. (Pubmed Central) -  Mar 17, 2020   
    PFS in our non-trial population was significantly shorter than in the SELECT trial population. In the interpretation of results, differences in the real life population and the SELECT study population regarding patient characteristics should be taken into account.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Bilateral Pneumothoraces Secondary to Lenvatinib (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area H) -  Mar 15, 2020 - Abstract #ATS2020ATS_9269;    
    The pneumothorax may resolve with drainage and discontinuation of the TKI. While rare, it is important to recognize tumor necrosis secondary to multi-site targeting TKI can be a cause of recurrent and persistent pneumothoraces.
  • ||||||||||  Nexavar (sorafenib) / Bayer, Amgen
    Biomarker, Clinical, Review, Journal:  Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib. (Pubmed Central) -  Mar 14, 2020   
    Unlike other targeted therapies, predictive and prognostic markers in HCC patients treated with sorafenib are lacking. Their identification could help clinicians in the daily management of these patients, mostly in light of the new therapeutic options available in the first.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    What about lenvatinib? (Twitter) -  Mar 11, 2020   
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS
    Evaluation of Palbociclib Dosing in Novel Oncologic Combination Therapies at UC San Diego Medical Center () -  Mar 9, 2020 - Abstract #HOPA2020HOPA_253;    
    Our preliminary analysis demonstrated that the majority of the patients on palbociclib combination therapy achieved a tolerable dose and the most commonly prescribed dose was 75 mg daily 3 weeks on and 1 week off, a 60% dose reduction. This study can provide guidance for appropriate starting doses for palbociclib in novel combination therapy as part of a precision medicine approach.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Clinical, Journal:  Current and emerging first-line systemic therapies in metastatic clear-cell renal cell carcinoma. (Pubmed Central) -  Mar 8, 2020   
    Nivolumab/ipilimumab (dual checkpoint inhibitors) seem to be the preferred first-line therapy in poor-risk patients, although cabozantinib, temsirolimus, sunitinib and pazopanib are also recommended...These emerging therapies include the combinations of pembrolizumab/lenvatinib, pembrolizumab/axitinib, avelumab/axitinib and atezolizumab/ bevacizu-mab and seem to introduce the mccRCC therapy in a new auspicious era. Moreover, emerging new targeted therapies and other, beyond ICIs, immunotherapies are currently underway.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Review, Journal:  Potential Mechanisms of Cancer-Related Hypercoagulability. (Pubmed Central) -  Mar 4, 2020   
    Several medications for cancer are correlated with a high risk of thrombosis. These include hormonal therapy (e.g., tamoxifen), chemotherapy (e.g., cisplatin, thalidomide and asparaginase), molecular targeted therapy (e.g., lenvatinib, osimertinib), and anti-angiogenesis monoclonal antibodies (e.g., bevacizumab and ramucirumab).
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Journal, Checkpoint inhibition:  Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges. (Pubmed Central) -  Mar 3, 2020   
    Sorafenib has been the standard of care for a decade, and promising results for regorafenib as a second-line and lenvatinib as a first-line treatment were reported only 1 or 2 years ago...The approval of nivolumab by the U.S. Food and Drug Administration on September 23, 2017, for the treatment of patients with HCC, based only on a phase I/II clinical trial, is a strong hint that immunotherapy will introduce a new era of HCC therapy...In virus-related HCC, especially hepatitis B virus-related HCC, whether CPIs can control virus relapse should be further investigated. Combination strategies involving conventional therapies and immunotherapies are needed to increase clinical benefit and minimize adverse toxicities with regard to the underlying liver disease.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD), Nexavar (sorafenib) / Bayer, Amgen
    Review, Journal:  Cancer nanotechnology: Enhancing tumor cell response to chemotherapy for hepatocellular carcinoma therapy. (Pubmed Central) -  Mar 1, 2020   
    It highlights the opportunities and challenges faced by nanotechnologies in contemporary hepatocellular carcinoma therapy, where personalized medicine is increasingly becoming the mainstay. Overall objective of this review is to enhance our understanding in the design and development of nanotechnology for treatment of HCC.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Novel combinations to overcome lenvatinib therapy resistance in thyroid cancer models in vitro and in vivo (The Westin Kierland Resort and Spa) -  Feb 27, 2020 - Abstract #MHNCS2020MHNCS_292;    
    Selinexor given at sub-optimal doses (10 mg/kgx2x3wks) or KPT-9274 (100 mg/kg BIDx5x3wks) when combined with lenvatinib (50 mg/kg BIDx5x3wks) showed superior anti-tumor activity in 8505 sub-cutaneous xenograft. These studies bring forward a novel combination for lenvatinib resistant thyroid cancers that warrant further clinical investigations.